Gesund collaborates with the Institute for Better Health, enabling AI developers to test models on real-world data

  • Gesund and the Institute for Better Health (IBH) at Trillium Health Partners (THP) collaborate to enable AI developers to test their models using real-world data.
  • Dr. Robert Carliff, FDA Commissioner, emphasizes the need for continuous evaluation of medical AI for safety and fairness.
  • Gesund’s MLOps platform facilitates third-party validation of AI, aiming to transition research-grade AI to clinical-grade AI efficiently.
  • The partnership allows AI developers to evaluate their models with physician experts at IBH, ensuring adherence to ethical standards.
  • THP, known for delivering high-quality patient care, houses IBH, dedicated to advancing healthcare through innovation.
  • Gesund’s CEO highlights the transformative potential of medical AI in enhancing healthcare delivery.
  • Gesund.ai’s recent activities include joining VALID AI and being selected for the CancerX Accelerator initiative.

Main AI News:

Gesund, the pioneer in ensuring the safety, fairness, and efficacy of medical artificial intelligence (AI) for all, unveils its groundbreaking collaboration with the Institute for Better Health (IBH) at Trillium Health Partners (THP), a premier healthcare system in Toronto. This unprecedented partnership allows AI developers to test their models using IBH’s real-world data in conjunction with Gesund.ai’s innovative technology, offering invaluable insights into model performance and areas for enhancement, such as bias and blind spots.

Earlier this year, Dr. Robert Carliff, the FDA Commissioner, emphasized the necessity of continuous evaluation to guarantee the safety and fairness of medical AI. He stressed the importance of a collaborative effort among various entities to ensure certification that AI algorithms contribute positively to healthcare.

From its inception, Gesund.ai has championed this perspective, spearheading the world’s inaugural AI Assurance Network through its pioneering MLOps platform. This platform aims to expedite the transformation of research-grade AI into clinical-grade AI by tenfold. Gesund employs its proprietary platform to provide leading third-party validation of AI, catering to pharmaceutical and medical device companies, as well as other AI developers.

Gesund and IBH are extending a unique opportunity to AI developers to assess their models with the guidance of esteemed physician experts committed to the highest standards of ethics, privacy, and security. This collaboration allows developers to test their solutions at IBH, which serves a diverse and expanding population.

THP, renowned for its commitment to delivering accessible, sustainable, and innovative patient care, serves as the backdrop for IBH’s research and innovation endeavors. IBH is dedicated to creating a new standard of healthcare through cutting-edge science, innovative strategies, and strategic partnerships.

Dr. Ben Fine, Clinician Scientist at IBH’s AI Deployment and Evaluation Lab, underscores the significance of Gesund’s platform in facilitating collaborative and ethical model evaluation. He emphasizes the platform’s transparency, responsibility, and reproducibility.

Enes Hosgor, Ph.D., founder & CEO of Gesund, highlights the transformative potential of medical AI in revolutionizing healthcare delivery. He emphasizes the importance of leveraging diverse, high-quality data for frequent validation to foster trust, safety, and patient equity. The partnership with THP marks a significant step towards bridging the gap between AI development and clinical implementation in healthcare.

This announcement follows a flurry of activity for Gesund.ai this year. In February, the company joined VALID AI, a coalition of 60 U.S. health systems dedicated to trustworthy AI practices. Additionally, at VIVE 2024, Gesund.ai was selected as one of the inaugural companies in the CancerX Accelerator, an initiative spearheaded by the White House to accelerate cancer research and innovation.

Conclusion:

This partnership between Gesund and IBH signifies a significant advancement in the evaluation and validation of medical AI models. By leveraging real-world data and expert guidance, AI developers can enhance the safety, fairness, and efficacy of their models, thus driving innovation in healthcare delivery. The collaboration also underscores the growing importance of ethical and transparent AI practices in the healthcare industry, paving the way for future advancements and partnerships in the market.

Source